Annexin A2 Combined with TTK Accelerates Esophageal Cancer Progression Via the Akt/mTOR Signaling Pathway

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Apr 24

PMID 38658569

Authors

Ruiqi Liu

Yanwei Lu

Jing Li

Weiping Yao

Jiajun Wu

Xiaoyan Chen

Luanluan Huang

Ding Nan

Yitian Zhang

Weijun Chen

Ying Wang

Yongshi Jia

Jianming Tang

Xiaodong Liang

Haibo Zhang

Affiliations

Soon will be listed here.

Abstract

Annexin A2 (ANXA2) is a widely reported oncogene. However, the mechanism of ANXA2 in esophageal cancer is not fully understood. In this study, we provided evidence that ANXA2 promotes the progression of esophageal squamous cell carcinoma (ESCC) through the downstream target threonine tyrosine kinase (TTK). These results are consistent with the up-regulation of ANXA2 and TTK in ESCC. In vitro experiments by knockdown and overexpression of ANXA2 revealed that ANXA2 promotes the progression of ESCC by enhancing cancer cell proliferation, migration, and invasion. Subsequently, animal models also confirmed the role of ANXA2 in promoting the proliferation and metastasis of ESCC. Mechanistically, the ANXA2/TTK complex activates the Akt/mTOR signaling pathway and accelerates epithelial-mesenchymal transition (EMT), thereby promoting the invasion and metastasis of ESCC. Furthermore, we identified that TTK overexpression can reverse the inhibition of ESCC invasion after ANXA2 knockdown. Overall, these data indicate that the combination of ANXA2 and TTK regulates the activation of the Akt/mTOR pathway and accelerates the progression of ESCC. Therefore, the ANXA2/TTK/Akt/mTOR axis is a potential therapeutic target for ESCC.

Citing Articles

METTL3/IGF2BP2 Promotes the Malignant Progression of Esophageal Cancer by Activating the PIK3CA/AKT Pathway.

Guo X, Huang A, Qi Y, Chen J, Yang M, Jin M Thorac Cancer. 2025; 16(4):e70022.

PMID: 39980152 PMC: 11842509. DOI: 10.1111/1759-7714.70022.

Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA-Seq and Bulk RNA-Seq: A Model Development and Validation Study.

Zhang J, Song S, Li Y, Gong A Cancer Med. 2025; 14(2):e70617.

PMID: 39840762 PMC: 11751878. DOI: 10.1002/cam4.70617.

Targeting TTK Inhibits Tumorigenesis of T-Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway.

Liu B, Lu T, Ding M, Zhou X, Jiang Y, Shang J Adv Sci (Weinh). 2025; 12(10):e2413990.

PMID: 39836493 PMC: 11905054. DOI: 10.1002/advs.202413990.

Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.

Weijie S Discov Oncol. 2024; 15(1):783.

PMID: 39692932 PMC: 11655786. DOI: 10.1007/s12672-024-01693-8.

Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.

Calheiros-Lobo M, Silva J, Pinto B, Monteiro L, Silva P, Bousbaa H Pharmaceutics. 2024; 16(9).

PMID: 39339232 PMC: 11435222. DOI: 10.3390/pharmaceutics16091196.

References

Liang X, Dai Y, Li Z, Gan M, Zhang S, Yin-Pan . Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma. PLoS One. 2014; 9(6):e97739. PMC: 4048189. DOI: 10.1371/journal.pone.0097739. View

Qi G, Ma H, Li Y, Peng J, Chen J, Kong B . TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway. Cell Death Dis. 2021; 12(12):1135. PMC: 8651821. DOI: 10.1038/s41419-021-04429-6. View

Liu X, Liao W, Yuan Q, Ou Y, Huang J . TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. Oncotarget. 2015; 6(33):34309-20. PMC: 4741454. DOI: 10.18632/oncotarget.5295. View

Li Y, Li X, Li L, Zhou R, Sikong Y, Gu X . S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer. Front Cell Dev Biol. 2020; 8:559486. PMC: 7726224. DOI: 10.3389/fcell.2020.559486. View

Lu Y, Li X, Liu H, Xue J, Zeng Z, Dong X . β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma. Oncogene. 2021; 40(7):1269-1283. PMC: 7892348. DOI: 10.1038/s41388-020-01596-2. View

Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K . Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012; 120(5):1087-94. DOI: 10.1182/blood-2012-03-415588. View

Li Z, Pan Y, Yao J, Gao Y, Qian Y, Zheng M . ANXA2 as a novel substrate of FBXW7 promoting esophageal squamous cell carcinoma via ERK phosphorylation. Biochem Biophys Res Commun. 2023; 649:93-100. DOI: 10.1016/j.bbrc.2023.01.082. View

Beyene D, Naab T, Kanarek N, Apprey V, Esnakula A, Khan F . Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men. Prostate. 2018; 78(11):801-811. PMC: 7257440. DOI: 10.1002/pros.23537. View

Anderhub S, Mak G, Gurden M, Faisal A, Drosopoulos K, Walsh K . High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Mol Cancer Ther. 2019; 18(10):1696-1707. DOI: 10.1158/1535-7163.MCT-18-1203. View

10.

Chaudhary P, Gibbs L, Maji S, Lewis C, Suzuki S, Vishwanatha J . Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. Breast Cancer Res. 2020; 22(1):31. PMC: 7087376. DOI: 10.1186/s13058-020-01268-9. View

11.

Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F . Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56(23):3203-3221.e11. DOI: 10.1016/j.devcel.2021.11.006. View

12.

Huang S, Chen Y, Lin Y, Yeh C . Clinical Limitations of Tissue Annexin A2 Level as a Predictor of Postoperative Overall Survival in Patients with Hepatocellular Carcinoma. J Clin Med. 2021; 10(18). PMC: 8465313. DOI: 10.3390/jcm10184158. View

13.

Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y . Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer Res. 2017; 77(23):6704-6716. DOI: 10.1158/0008-5472.CAN-17-1915. View

14.

Chen C, Lin Y, Chen C, Chen Y . Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. J Biomed Sci. 2018; 25(1):30. PMC: 5877395. DOI: 10.1186/s12929-018-0430-8. View

15.

Schulze V, Klar U, Kosemund D, Wengner A, Siemeister G, Stockigt D . Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. J Med Chem. 2020; 63(15):8025-8042. DOI: 10.1021/acs.jmedchem.9b02035. View

16.

Zhang H, Zeng Q, Wu B, Lu J, Tong K, Lin J . TRIM21-regulated Annexin A2 plasma membrane trafficking facilitates osteosarcoma cell differentiation through the TFEB-mediated autophagy. Cell Death Dis. 2021; 12(1):21. PMC: 7790825. DOI: 10.1038/s41419-020-03364-2. View

17.

Abdelraouf E, Hussein R, Shaaban A, El-Sherief H, Embaby A, El-Aleem S . Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. Life Sci. 2022; 308:120967. DOI: 10.1016/j.lfs.2022.120967. View

18.

Mason J, Wei X, Fletcher G, Kiarash R, Brokx R, Hodgson R . Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017; 114(12):3127-3132. PMC: 5373378. DOI: 10.1073/pnas.1700234114. View

19.

Fang Q, Chen X, Zhang L, Li Y, Sun T, Yang C . The essential roles of Mps1 in spermatogenesis and fertility in mice. Cell Death Dis. 2021; 12(6):531. PMC: 8144579. DOI: 10.1038/s41419-021-03815-4. View

20.

Atrafi F, Boix O, Subbiah V, Diamond J, Chawla S, Tolcher A . Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clin Cancer Res. 2022; 28(13):2969. DOI: 10.1158/1078-0432.CCR-22-1792. View